NASDAQ:ANCN

Anchiano Therapeutics Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.

$30.23

-0.16 (-0.53 %)

(As of 04/21/2021 12:00 AM ET)

Add

Compare

Today's Range

$28.28

Now: $30.23▼

$32.50

50-Day Range

$2.82

MA: $21.77▼

$59.00

52-Week Range

$0.51

Now: $30.23▼

$10.55

Volume147,970 shs

Average Volume3.15 million shs

Market Capitalization$224.31 million

P/E Ratio201.53

Dividend YieldN/A

Beta0.93

Anchiano Therapeutics Ltd., a preclinical biotechnology company, discovers, develops, and commercializes small molecule anti-cancer therapies. It primarily develops Pan-RAS Program that identifies novel indene-based small molecules that exhibit potent and selective inhibition of activated RAS signaling regardless of isoform or mutation; and PDE10/Ã-catenin program, which identifies small molecules that selectively and potently inhibit PDE10 and suppress Wnt/APC/Ã-catenin signaling in preclinical models. Anchiano Therapeutics Ltd. has collaboration and license agreement with ADT Pharmaceuticals, LLC to research and develop programs related to the pan-RAS and PDE10/Ã-catenin programs. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd. in July 2018. Anchiano Therapeutics Ltd. was founded in 2004 and is headquartered in Cambridge, Massachusetts.

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:ANCN

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.anchiano.com

Phone857-259-4622

Employees16

Year FoundedN/A

Debt

Debt-to-Equity RatioN/A

Current Ratio3.25

Quick Ratio3.25

Price-To-Earnings

Trailing P/E Ratio201.53

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$2.01 per share

Price / Book15.04

Profitability

EPS (Most Recent Fiscal Year)($3.46)

Net Income$-27,120,000.00

Net MarginsN/A

Return on Equity36.08%

Return on Assets27.40%

Miscellaneous

Outstanding Shares7,420,000

Market Cap$224.31 million

Next Earnings Date5/6/2021 (Estimated)

OptionableNot Optionable

Headlines

Genesis Prize Co-Founder Stan Polovets Steps Down as Chairman of Anchiano Therapeutics after Company Posts 630% Return in 12 Months
March 22, 2021 | finance.yahoo.com

Anchiano Therapeutics: Anchiano Announces Shareholder Approval of the Merger with Chemomab and Prices $45.5M Private Financing
March 16, 2021 | finanznachrichten.de

Anchiano Announces Shareholder Approval of the Merger with Chemomab and Prices $45.5M Private Financing
March 15, 2021 | finance.yahoo.com

Why Immunovant, Anchiano, OpGen Are Rallying Today
March 8, 2021 | markets.businessinsider.com

5 Penny Stocks To Watch This Week As Biotech Takes Spotlight
March 7, 2021 | marketwatch.com

Anchiano Therapeutics Ltd. ADR
February 6, 2021 | barrons.com

ANCHIANO THERAPEUTICS LTD (spons. ADRs) Stock , ANCN
February 5, 2021 | markets.businessinsider.com

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Reminds Investors of Investigations of ANCN, JWS, GXGX, and ALSK Mergers
January 26, 2021 | feeds.benzinga.com

ANCHIANO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Anchiano Therapeutics Ltd. - ANCN
January 16, 2021 | finance.yahoo.com

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Anchiano Therapeutics Ltd. - ANCN
January 13, 2021 | finance.yahoo.com

SHAREHOLDER ALERT: WeissLaw LLP Reminds CHNG, CPAH, CATM, and ANCN Shareholders About Its Ongoing Investigations
January 13, 2021 | finance.yahoo.com

SHAREHOLDER ALERT: WeissLaw LLP Reminds ANCN, PRVL, BRPA, and TPGY Shareholders About Its Ongoing Investigations
December 22, 2020 | finance.yahoo.com

SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Anchiano Therapeutics Ltd. Merger
December 17, 2020 | benzinga.com

SHAREHOLDER ALERT: WeissLaw LLP Investigates Anchiano Therapeutics Ltd.
December 15, 2020 | finance.yahoo.com

Why Anchiano Therapeutics Is Trading Higher Today
December 15, 2020 | benzinga.com

Stock Alert: Anchiano Therapeutics Soars 130% On Merger Deal With Chemomab
December 15, 2020 | nasdaq.com

Anchiano Therapeutics and Chemomab Announce Entry Into Definitive Merger Agreement
December 15, 2020 | finance.yahoo.com

All You Need to Know About Anchiano Therapeutics Ltd. Sponsored ADR (ANCN) Rating Upgrade to Buy
October 8, 2020 | nasdaq.com

Anchiano Therapeutics Ltd. American Depositary Share (ANCN)
August 17, 2020 | nasdaq.com

Anchiano Appoints Stan Polovets as Chairman of the Board
May 26, 2020 | finance.yahoo.com

See More Headlines

MarketRank^™

Overall MarketRank^™

0.83 out of 5 stars

Medical Sector

1177th out of 2,024 stocks

Pharmaceutical Preparations Industry

527th out of 771 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Anchiano Therapeutics.

2.5 Community Rank

Outperform Votes
Anchiano Therapeutics has received 58 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Anchiano Therapeutics has received 60 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Anchiano Therapeutics has received 50.85% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Anchiano Therapeutics and other stocks. Vote “Outperform” if you believe ANCN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ANCN will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Anchiano Therapeutics does not currently pay a dividend.
Dividend Growth
Anchiano Therapeutics does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Anchiano Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $99,998.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 6.88% of the stock of Anchiano Therapeutics is held by insiders.
Percentage Held by Institutions
Only 9.05% of the stock of Anchiano Therapeutics is held by institutions.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Anchiano Therapeutics are expected to decrease in the coming year, from ($1.81) to ($3.10) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Anchiano Therapeutics is 201.53, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 23.73.
Price to Earnings Ratio vs. Sector
The P/E ratio of Anchiano Therapeutics is 201.53, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 45.16.
Price to Book Value per Share Ratio
Anchiano Therapeutics has a P/B Ratio of 15.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Receive ANCN News and Ratings via Email

Sign-up to receive the latest news and ratings for ANCN and its competitors with MarketBeat's FREE daily newsletter.

Anchiano Therapeutics (NASDAQ:ANCN) Frequently Asked Questions

What stocks does MarketBeat like better than Anchiano Therapeutics?

Wall Street analysts have given Anchiano Therapeutics a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Anchiano Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Anchiano Therapeutics' next earnings date?

Anchiano Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Anchiano Therapeutics.

How were Anchiano Therapeutics' earnings last quarter?

Anchiano Therapeutics Ltd. (NASDAQ:ANCN) posted its earnings results on Monday, August, 5th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.12.
View Anchiano Therapeutics' earnings history.

Who are Anchiano Therapeutics' key executives?

Anchiano Therapeutics' management team includes the following people:

Mr. Ronald K. Knickerbocker, Sr. VP of Clinical Devel. & Data Sciences (Age 55, Pay $352k)
Mr. Neil H. Cohen, CEO & Director (Age 58)
Prof. Abraham Hochberg, Co-Founder & Chief Scientific Officer (Age 83)
Mr. Andrew Fine, Chief Financial Officer (Age 51)
Mr. Avraham Hampel M.B.A., Deputy CFO & Company Sec.
Mr. Or Dolev, Controller (Age 43)

Who are some of Anchiano Therapeutics' key competitors?

Some companies that are related to Anchiano Therapeutics include Dyne Therapeutics (DYN), Merus (MRUS), ESSA Pharma (EPIX), Vectura Group (VEGPF), BioXcel Therapeutics (BTAI), Annexon (ANNX), Amphastar Pharmaceuticals (AMPH), ADVANZ PHARMA (CXRXF), Collegium Pharmaceutical (COLL), Ardelyx (ARDX), ORIC Pharmaceuticals (ORIC), Humanigen (HGEN), Epizyme (EPZM), Esperion Therapeutics (ESPR) and Lexicon Pharmaceuticals (LXRX).
View all of ANCN's competitors.

What other stocks do shareholders of Anchiano Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Anchiano Therapeutics investors own include AbbVie (ABBV), Allena Pharmaceuticals (ALNA), Aileron Therapeutics (ALRN), Abeona Therapeutics (ABEO), Aurora Cannabis (ACB), Achieve Life Sciences (ACHV), Acorda Therapeutics (ACOR), Acasti Pharma (ACST), Aduro Biotech (ADRO) and AnaptysBio (ANAB).

When did Anchiano Therapeutics IPO?

(ANCN) raised $35 million in an initial public offering (IPO) on Tuesday, February 12th 2019. The company issued 2,400,000 shares at a price of $14.55 per share. Oppenheimer acted as the underwriter for the IPO and Ladenburg Thalmann was co-manager.

What is Anchiano Therapeutics' stock symbol?

Anchiano Therapeutics trades on the NASDAQ under the ticker symbol "ANCN."

What is Anchiano Therapeutics' stock price today?

One share of ANCN stock can currently be purchased for approximately $30.23.

How much money does Anchiano Therapeutics make?

Anchiano Therapeutics has a market capitalization of $224.31 million. The company earns $-27,120,000.00 in net income (profit) each year or ($3.46) on an earnings per share basis.

How many employees does Anchiano Therapeutics have?

Anchiano Therapeutics employs 16 workers across the globe.

What is Anchiano Therapeutics' official website?

The official website for Anchiano Therapeutics is www.anchiano.com.

Where are Anchiano Therapeutics' headquarters?

Anchiano Therapeutics is headquartered at ONE KENDALL SQUARE BUILDING 400 SUITE 14-105, CAMBRIDGE MA, 02139.

How can I contact Anchiano Therapeutics?

Anchiano Therapeutics' mailing address is ONE KENDALL SQUARE BUILDING 400 SUITE 14-105, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-4622 or via email at [email protected]

This page was last updated on 4/22/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Anchiano Therapeutics Stock Forecast, Price & News

Adding

Adding

Adding Anchiano Therapeutics Ltd.

Industry, Sector and Symbol

Debt

Price-To-Earnings

Sales & Book Value

Profitability

Miscellaneous

Headlines

MarketRank™

Overall MarketRank™

0.0 Analyst's Opinion

2.5 Community Rank

Outperform Votes

Underperform Votes

Community Sentiment

0.0 Dividend Strength

1.7 Company Ownership

0.0 Earnings and Valuation

Receive ANCN News and Ratings via Email

Anchiano Therapeutics (NASDAQ:ANCN) Frequently Asked Questions

What stocks does MarketBeat like better than Anchiano Therapeutics?

When is Anchiano Therapeutics' next earnings date?

How were Anchiano Therapeutics' earnings last quarter?

Who are Anchiano Therapeutics' key executives?

Who are some of Anchiano Therapeutics' key competitors?

What other stocks do shareholders of Anchiano Therapeutics own?

When did Anchiano Therapeutics IPO?

What is Anchiano Therapeutics' stock symbol?

What is Anchiano Therapeutics' stock price today?

How much money does Anchiano Therapeutics make?

How many employees does Anchiano Therapeutics have?

What is Anchiano Therapeutics' official website?

Where are Anchiano Therapeutics' headquarters?

How can I contact Anchiano Therapeutics?

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

MarketRank^™

Overall MarketRank^™